# Extranodal Lymphoplasmacytic Lymphoma Responding Rapidly to Zanubrutinib: A Case Series

## TL;DR

This paper reports three cases of rare lymphoma responding well to a drug called Zanubrutinib.

## Contribution

The study highlights the effectiveness of Zanubrutinib in treating atypical extranodal lymphoplasmacytic lymphoma.

## Key findings

- Three patients with atypical extranodal lymphoplasmacytic lymphoma showed rapid responses to Zanubrutinib.
- Zanubrutinib was associated with a limited side effect profile in these cases.
- The results suggest Zanubrutinib as a promising treatment option for this rare lymphoma subtype.

## Abstract

Management of recurrent or atypical lymphoplasmacytic lymphoma poses a significant therapeutic challenge. Here we demonstrate a case series of three patients with atypical presentations of extranodal lymphoplasmacytic lymphoma that each show remarkable and timely responses to Zanubrutinib with a limited side effect profile.